THU0176 Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Abstract

ObjectivesTo present analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab (GLM) Ph3 SC trials across rheumatological indications.MethodsSC placebo (PBO) or GLM (50mg or100mg) was administered...